Addendum

Bimekizumab (plaque psoriasis) - Addendum to Commission A21-110

Report documents

Indication:

Adult patients with moderate to severe plaque psoriasis

Result of dossier assessment:

After addendum:

Patients who are not candidates for conventional treatment in the framework of a first systemic therapy: hint of minor added benefit.
Patients who have had an inadequate response or who have been intolerant to systemic therapy: proof of minor added benefit.

Federal Joint Committee (G-BA)

2022-03-03 A G-BA decision was published.

Project no.: A22-07
Commission: Commission awarded on 25.01.2022 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Skin and hair
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.